StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) income statement

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3015% below fair value
$1.94−0.10 (-4.90%)

Close on Nov 18, 2026Market cap $153.50MP/E 16.2Yield –

Niagen Bioscience, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
63.9%
Operating margin
3.9%
Net margin
8.4%
Return on equity, FY2025
28.3%

Financial strength

Current ratio
5.93
Debt to equity
–
Debt to assets
–
Cash to current liabilities
411.1%

Valuation

P/E ratio
16.2
Price to sales
1.26
Price to book
1.85
Dividend yield
–

See a number that looks wrong?